Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2009
The October issue of Archives included what we consider a landmark article by McIntyre and Jerrell.1 As clinicians involved in the evaluation of mentally ill youth, many of whom present for care taking multiple psychoactive medications for dubious indications, we are alarmed by the authors' finding that antipsychotic agents in particular are associated with serious cardiometabolic morbidity in children and adolescents, as they are in adults.2,3 Their findings are all the more impressive given the relatively high medical morbidity in the untreated control group, with whom the subjects taking antipsychotic agents were compared. In light of the aggressive off-label marketing of antipsychotic drugs to physicians involved in both state-managed and private health care programs for youth, it is particularly important that both mental health specialists and primary care physicians be aware of these data.
Kruszewski SP, Paczynski RP. Antipsychotic Agents and Cardiometabolic Morbidity in Youth. Arch Pediatr Adolesc Med. 2009;163(4):394–395. doi:10.1001/archpediatrics.2009.28
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: